Ask a Question

User doubthand95

Member for: 1 month (since Mar 16)
Type: Registered user
Full name:
Location:
About: First-Line Nivolumab Additionally Ipilimumab inside Innovative Non-Small Cellular Cancer of the lung: 4-Year Outcomes In the Randomized, Open-Label, Period Three CheckMate 227 Component One Tryout.

Activity by doubthand95

Score: 0 points
Title: Newbie
Questions: 0
Answers: 0
Comments: 0
Voted on: 0 questions, 0 answers
Gave out: 0 up votes, 0 down votes
Received: 0 up votes, 0 down votes

Wall for doubthand95

Please log in or register to post on this wall.
Snow Theme by Q2A Market
Powered by Question2Answer
...